

# Todd Lencz

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1718362/publications.pdf>

Version: 2024-02-01

222  
papers

31,908  
citations

8755

77  
h-index

5739

167  
g-index

259  
all docs

259  
docs citations

259  
times ranked

34659  
citing authors

#	ARTICLE	IF	CITATIONS
1	Sex-Dependent Shared and Nonshared Genetic Architecture Across Mood and Psychotic Disorders. <i>Biological Psychiatry</i> , 2022, 91, 102-117.	0.7	61
2	Striatal functional connectivity in psychosis relapse: A hypothesis generating study. <i>Schizophrenia Research</i> , 2022, 243, 342-348.	1.1	9
3	Capacities and Limitations of Using Polygenic Risk Scores for Reproductive Decision Making. <i>American Journal of Bioethics</i> , 2022, 22, 42-45.	0.5	2
4	Mapping genomic loci implicates genes and synaptic biology in schizophrenia. <i>Nature</i> , 2022, 604, 502-508.	13.7	929
5	Complement component C4 levels in the cerebrospinal fluid and plasma of patients with schizophrenia. <i>Neuropsychopharmacology</i> , 2021, 46, 1140-1144.	2.8	24
6	Multivariate genome-wide analysis of education, socioeconomic status and brain phenome. <i>Nature Human Behaviour</i> , 2021, 5, 482-496.	6.2	30
7	Screening embryos for polygenic conditions and traits: ethical considerations for an emerging technology. <i>Genetics in Medicine</i> , 2021, 23, 432-434.	1.1	36
8	Divergent and self-reactive immune responses in the CNS of COVID-19 patients with neurological symptoms. <i>Cell Reports Medicine</i> , 2021, 2, 100288.	3.3	121
9	Novel ultra-rare exonic variants identified in a founder population implicate cadherins in schizophrenia. <i>Neuron</i> , 2021, 109, 1465-1478.e4.	3.8	21
10	Identifying nootropic drug targets via large-scale cognitive GWAS and transcriptomics. <i>Neuropsychopharmacology</i> , 2021, 46, 1788-1801.	2.8	12
11	Genome wide study of tardive dyskinesia in schizophrenia. <i>Translational Psychiatry</i> , 2021, 11, 351.	2.4	13
12	Large-scale evaluation of the Positive and Negative Syndrome Scale (PANSS) symptom architecture in schizophrenia. <i>Asian Journal of Psychiatry</i> , 2021, 62, 102732.	0.9	29
13	Utility of polygenic embryo screening for disease depends on the selection strategy. <i>ELife</i> , 2021, 10, .	2.8	34
14	ECT-induced cognitive side effects are associated with hippocampal enlargement. <i>Translational Psychiatry</i> , 2021, 11, 516.	2.4	24
15	Contributions of parasympathetic arousal-related activity to cognitive performance in First Episode Psychosis patients and controls. <i>Biological Psychiatry: Cognitive Neuroscience and Neuroimaging</i> , 2021, , .	1.1	2
16	Parasympathetic arousal-related cortical activity is associated with attention during cognitive task performance. <i>NeuroImage</i> , 2020, 208, 116469.	2.1	21
17	Interaction of Cannabis Use Disorder and Striatal Connectivity in Antipsychotic Treatment Response. <i>Schizophrenia Bulletin Open</i> , 2020, 1, sgaa014.	0.9	5
18	The effects of lorazepam on cortico-striatal connectivity in schizophrenia. <i>Schizophrenia Research</i> , 2020, 223, 363-365.	1.1	1

#	ARTICLE	IF	CITATIONS
19	Leveraging correlations between variants in polygenic risk scores to detect heterogeneity in GWAS cohorts. <i>PLoS Genetics</i> , 2020, 16, e1009015.	1.5	4
20	Title is missing!. , 2020, 16, e1009015.		0
21	Title is missing!. , 2020, 16, e1009015.		0
22	Title is missing!. , 2020, 16, e1009015.		0
23	Title is missing!. , 2020, 16, e1009015.		0
24	Title is missing!. , 2020, 16, e1009015.		0
25	Title is missing!. , 2020, 16, e1009015.		0
26	Variation within voltage-gated calcium channel genes and antipsychotic treatment response in a South African first episode schizophrenia cohort. <i>Pharmacogenomics Journal</i> , 2019, 19, 109-114.	0.9	7
27	Frontal lobe functioning during a simple response conflict task in first-episode psychosis and its relationship to treatment response. <i>Brain Imaging and Behavior</i> , 2019, 13, 541-553.	1.1	11
28	Pleiotropic Meta-Analysis of Cognition, Education, and Schizophrenia Differentiates Roles of Early Neurodevelopmental and Adult Synaptic Pathways. <i>American Journal of Human Genetics</i> , 2019, 105, 334-350.	2.6	86
29	Striatal volume and functional connectivity correlate with weight gain in early-phase psychosis. <i>Neuropsychopharmacology</i> , 2019, 44, 1948-1954.	2.8	16
30	LARGE-SCALE GWAS META-ANALYSIS AND MULTI-TRAIT ANALYSIS YIELDS DOZENS OF NOVEL LOCI AND NOVEL GENETIC CORRELATES FOR GENERAL COGNITIVE ABILITY. <i>European Neuropsychopharmacology</i> , 2019, 29, S808-S809.	0.3	0
31	T175. The Effects of Lorazepam on Resting-State Functional Connectivity. <i>Biological Psychiatry</i> , 2019, 85, S197.	0.7	0
32	92 NOVEL ULTRA-RARE EXONIC VARIANTS IDENTIFIED IN A FOUNDER POPULATION IMPLICATE CADHERINS, PROTOCADHERINS, AND AUTISM/ID GENES IN SCHIZOPHRENIA. <i>European Neuropsychopharmacology</i> , 2019, 29, S111.	0.3	0
33	46USING PLEIOTROPY TO DISSECT FUNCTIONAL PATHWAYS IN COGNITION, EDUCATION, AND SCHIZOPHRENIA. <i>European Neuropsychopharmacology</i> , 2019, 29, S1093.	0.3	0
34	SA51THE LIMITS OF POLYGENIC EMBRYO SELECTION FOR COGNITIVE ABILITY. <i>European Neuropsychopharmacology</i> , 2019, 29, S1215-S1216.	0.3	0
35	O10.8. STRIATAL CONNECTIVITY IN BREAKTHROUGH PSYCHOSIS ON ANTIPSYCHOTIC MAINTENANCE: PRELIMINARY RESULTS FROM THE BAMB STUDY. <i>Schizophrenia Bulletin</i> , 2019, 45, S193-S193.	2.3	0
36	O35. Relationship of Rich Club Organization and MCCB Reasoning Domain in First Episode Schizophrenia. <i>Biological Psychiatry</i> , 2019, 85, S120.	0.7	0

#	ARTICLE	IF	CITATIONS
37	International Society of Psychiatric Genetics Ethics Committee: Issues facing us. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2019, 180, 543-554.	1.1	16
38	Genome-wide Association Study of Maximum Habitual Alcohol Intake in >140,000 U.S. European and African American Veterans Yields Novel Risk Loci. Biological Psychiatry, 2019, 86, 365-376.	0.7	82
39	SCHIZOPHRENIA POLYGENIC RISK SCORE PREDICTS ANTIPSYCHOTIC TREATMENT RESPONSE IN PATIENTS WITH FIRST EPISODE PSYCHOSIS. European Neuropsychopharmacology, 2019, 29, S999.	0.3	0
40	Structural similarity networks predict clinical outcome in early-phase psychosis. Neuropsychopharmacology, 2019, 44, 915-922.	2.8	23
41	Age-Normative Pathways of Striatal Connectivity Related to Clinical Symptoms in the General Population. Biological Psychiatry, 2019, 85, 966-976.	0.7	26
42	F148. 301 Cognitive Loci Identified in Large-Scale GWAS Meta-Analysis. Biological Psychiatry, 2019, 85, S270.	0.7	1
43	M41 IDENTIFYING NOOTROPIC DRUG TARGETS VIA LARGE-SCALE COGNITIVE GWAS AND TRANSCRIPTOMICS. European Neuropsychopharmacology, 2019, 29, S187-S188.	0.3	0
44	Schizophrenia polygenic risk score and 20-year course of illness in psychotic disorders. Translational Psychiatry, 2019, 9, 300.	2.4	70
45	Screening Human Embryos for Polygenic Traits Has Limited Utility. Cell, 2019, 179, 1424-1435.e8.	13.5	78
46	Schizophrenia Polygenic Risk Score as a Predictor of Antipsychotic Efficacy in First-Episode Psychosis. American Journal of Psychiatry, 2019, 176, 21-28.	4.0	127
47	Apolipoprotein E- $\mu$ 4 allele predicts escalation of psychotic symptoms in late adulthood. Schizophrenia Research, 2019, 206, 82-88.	1.1	8
48	A simulations approach for meta-analysis of genetic association studies based on additive genetic model. Meta Gene, 2018, 16, 143-164.	0.3	1
49	Functional variants in the <i>LRRK2</i> gene confer shared effects on risk for Crohn's disease and Parkinson's disease. Science Translational Medicine, 2018, 10, .	5.8	273
50	High-depth whole genome sequencing of an Ashkenazi Jewish reference panel: enhancing sensitivity, accuracy, and imputation. Human Genetics, 2018, 137, 343-355.	1.8	24
51	F198. Parahippocampal Thickness Predicts Treatment Improvement in Early and Chronic Schizophrenia. Biological Psychiatry, 2018, 83, S315-S316.	0.7	0
52	Stress-Dependent Association Between Polygenic Risk for Schizophrenia and Schizotypal Traits in Young Army Recruits. Schizophrenia Bulletin, 2018, 44, 338-347.	2.3	33
53	S20. PARAHIPPOCAMPAL THICKNESS PREDICTS TREATMENT IMPROVEMENT IN EARLY AND CHRONIC SCHIZOPHRENIA. Schizophrenia Bulletin, 2018, 44, S330-S331.	2.3	0
54	Study of 300,486 individuals identifies 148 independent genetic loci influencing general cognitive function. Nature Communications, 2018, 9, 2098.	5.8	484

#	ARTICLE	IF	CITATIONS
55	O31. Age-Normative Pathways of Striatal Connectivity Relate to ADHD Symptoms in the General Population. <i>Biological Psychiatry</i> , 2018, 83, S121.	0.7	0
56	Genome-wide association meta-analysis in 269,867 individuals identifies new genetic and functional links to intelligence. <i>Nature Genetics</i> , 2018, 50, 912-919.	9.4	893
57	F10. DIFFERENTIAL EXPRESSION OF MICRORNAS IN CEREBROSPINAL FLUID AND PLASMA SAMPLES IN SCHIZOPHRENIA. <i>Schizophrenia Bulletin</i> , 2018, 44, S221-S222.	2.3	6
58	Gene discovery and polygenic prediction from a genome-wide association study of educational attainment in 1.1 million individuals. <i>Nature Genetics</i> , 2018, 50, 1112-1121.	9.4	1,835
59	Multi-Trait Analysis of GWAS and Biological Insights Into Cognition: A Response to Hill (2018). <i>Twin Research and Human Genetics</i> , 2018, 21, 394-397.	0.3	3
60	Cytokines in cerebrospinal fluid of patients with schizophrenia spectrum disorders: New data and an updated meta-analysis. <i>Schizophrenia Research</i> , 2018, 202, 64-71.	1.1	82
61	195. Fatty Acid Bioavailability and Membrane Dynamics are Associated With White Matter Integrity and Neurocognitive Performance During Development. <i>Biological Psychiatry</i> , 2018, 83, S78-S79.	0.7	0
62	T228. Identifying Key SNPs and Pathways Underlying Cognition, Education and Schizophrenia. <i>Biological Psychiatry</i> , 2018, 83, S217.	0.7	0
63	Genome-wide association study of cognitive flexibility assessed by the Wisconsin Card Sorting Test. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2018, 177, 511-519.	1.1	4
64	The Genetics of Endophenotypes of Neurofunction to Understand Schizophrenia (GENUS) consortium: A collaborative cognitive and neuroimaging genetics project. <i>Schizophrenia Research</i> , 2018, 195, 306-317.	1.1	17
65	Applications of temporal kernel canonical correlation analysis in adherence studies. <i>Statistical Methods in Medical Research</i> , 2017, 26, 2437-2454.	0.7	1
66	349. Neuroimaging Biomarkers of ECT Response. <i>Biological Psychiatry</i> , 2017, 81, S143.	0.7	0
67	Relationship between Duration of Untreated Psychosis and Intrinsic Corticostriatal Connectivity in Patients with Early Phase Schizophrenia. <i>Neuropsychopharmacology</i> , 2017, 42, 2214-2221.	2.8	55
68	Identification of Genetic Loci Jointly Influencing Schizophrenia Risk and the Cognitive Traits of Verbal-Numerical Reasoning, Reaction Time, and General Cognitive Function. <i>JAMA Psychiatry</i> , 2017, 74, 1065.	6.0	123
69	Large-Scale Cognitive GWAS Meta-Analysis Reveals Tissue-Specific Neural Expression and Potential Nootropic Drug Targets. <i>Cell Reports</i> , 2017, 21, 2597-2613.	2.9	103
70	The time and place of European admixture in Ashkenazi Jewish history. <i>PLoS Genetics</i> , 2017, 13, e1006644.	1.5	25
71	The identification of novel genetic variants associated with antipsychotic treatment response outcomes in first-episode schizophrenia patients. <i>Pharmacogenetics and Genomics</i> , 2016, 26, 235-242.	0.7	15
72	A Frameshift in CSF2RB Predominant Among Ashkenazi Jews Increases Risk for Crohn's Disease and Reduces Monocyte Signaling via GM-CSF. <i>Gastroenterology</i> , 2016, 151, 710-723.e2.	0.6	51

#	ARTICLE	IF	CITATIONS
73	Variants in the DRD2 locus and antipsychotic-related prolactin levels: A meta-analysis. <i>Psychoneuroendocrinology</i> , 2016, 72, 1-10.	1.3	31
74	Pharmacogenetic Associations of Antipsychotic Drug-Related Weight Gain: A Systematic Review and Meta-analysis. <i>Schizophrenia Bulletin</i> , 2016, 42, 1418-1437.	2.3	149
75	Subgenual cingulate cortical activity predicts the efficacy of electroconvulsive therapy. <i>Translational Psychiatry</i> , 2016, 6, e789-e789.	2.4	62
76	In Support of Neuroimaging Biomarkers of Treatment Response in First-Episode Schizophrenia. <i>American Journal of Psychiatry</i> , 2016, 173, 732-733.	4.0	8
77	Duration of attenuated positive and negative symptoms in individuals at clinical high risk: Associations with risk of conversion to psychosis and functional outcome. <i>Journal of Psychiatric Research</i> , 2016, 81, 95-101.	1.5	70
78	Limited Evidence for Association of Genome-Wide Schizophrenia Risk Variants on Cortical Neuroimaging Phenotypes. <i>Schizophrenia Bulletin</i> , 2016, 42, 1027-1036.	2.3	11
79	Genome-wide autozygosity is associated with lower general cognitive ability. <i>Molecular Psychiatry</i> , 2016, 21, 837-843.	4.1	62
80	Expanded genetic screening panel for the Ashkenazi Jewish population. <i>Genetics in Medicine</i> , 2016, 18, 522-528.	1.1	33
81	Baseline Striatal Functional Connectivity as a Predictor of Response to Antipsychotic Drug Treatment. <i>American Journal of Psychiatry</i> , 2016, 173, 69-77.	4.0	168
82	The Relationship of Common Risk Variants and Polygenic Risk for Schizophrenia to Sensorimotor Gating. <i>Biological Psychiatry</i> , 2016, 79, 988-996.	0.7	44
83	Independent evidence for an association between general cognitive ability and a genetic locus for educational attainment. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2015, 168, 363-373.	1.1	25
84	Genome-wide association study of schizophrenia in Ashkenazi Jews. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2015, 168, 649-659.	1.1	203
85	Targeting the schizophrenia genome: a fast track strategy from GWAS to clinic. <i>Molecular Psychiatry</i> , 2015, 20, 820-826.	4.1	89
86	Joint Analysis of Psychiatric Disorders Increases Accuracy of Risk Prediction for Schizophrenia, Bipolar Disorder, and Major Depressive Disorder. <i>American Journal of Human Genetics</i> , 2015, 96, 283-294.	2.6	225
87	Psychiatric genome-wide association study analyses implicate neuronal, immune and histone pathways. <i>Nature Neuroscience</i> , 2015, 18, 199-209.	7.1	701
88	Common variants of IRF3 conferring risk of schizophrenia. <i>Journal of Psychiatric Research</i> , 2015, 64, 67-73.	1.5	10
89	Antipsychotic Treatment and Functional Connectivity of the Striatum in First-Episode Schizophrenia. <i>JAMA Psychiatry</i> , 2015, 72, 5.	6.0	277
90	A Common Polymorphism in <i>SCN2A</i> Predicts General Cognitive Ability through Effects on PFC Physiology. <i>Journal of Cognitive Neuroscience</i> , 2015, 27, 1766-1774.	1.1	6

#	ARTICLE	IF	CITATIONS
91	Relationship of Cognition to Clinical Response in First-Episode Schizophrenia Spectrum Disorders. <i>Schizophrenia Bulletin</i> , 2015, 41, 1237-1247.	2.3	45
92	New data and an old puzzle: the negative association between schizophrenia and rheumatoid arthritis. <i>International Journal of Epidemiology</i> , 2015, 44, 1706-1721.	0.9	53
93	Association of a Schizophrenia Risk Variant at the <i>DRD2</i> Locus With Antipsychotic Treatment Response in First-Episode Psychosis. <i>Schizophrenia Bulletin</i> , 2015, 41, 1248-1255.	2.3	64
94	A Randomized Comparison of Aripiprazole and Risperidone for the Acute Treatment of First-Episode Schizophrenia and Related Disorders: 3-Month Outcomes. <i>Schizophrenia Bulletin</i> , 2015, 41, 1227-1236.	2.3	100
95	Brain White Matter Development Is Associated with a Human-Specific Haplotype Increasing the Synthesis of Long Chain Fatty Acids. <i>Journal of Neuroscience</i> , 2014, 34, 6367-6376.	1.7	27
96	The <i>SORL1</i> gene and convergent neural risk for Alzheimer's disease across the human lifespan. <i>Molecular Psychiatry</i> , 2014, 19, 1125-1132.	4.1	39
97	The <i>CSMD1</i> genome-wide associated schizophrenia risk variant rs10503253 affects general cognitive ability and executive function in healthy males. <i>Schizophrenia Research</i> , 2014, 154, 42-47.	1.1	42
98	A schizophrenia risk gene, <i>ZNF804A</i> , is associated with brain white matter microstructure. <i>Schizophrenia Research</i> , 2014, 155, 15-20.	1.1	22
99	Molecular genetic evidence for overlap between general cognitive ability and risk for schizophrenia: a report from the Cognitive Genomics consortium (COGENT). <i>Molecular Psychiatry</i> , 2014, 19, 168-174.	4.1	178
100	Genome-wide mapping of IBD segments in an Ashkenazi PD cohort identifies associated haplotypes. <i>Human Molecular Genetics</i> , 2014, 23, 4693-4702.	1.4	49
101	Biological insights from 108 schizophrenia-associated genetic loci. <i>Nature</i> , 2014, 511, 421-427.	13.7	6,934
102	Sequencing an Ashkenazi reference panel supports population-targeted personal genomics and illuminates Jewish and European origins. <i>Nature Communications</i> , 2014, 5, 4835.	5.8	156
103	<i>BDNF</i> Val66Met polymorphism and antipsychotic-induced tardive dyskinesia occurrence and severity: A meta-analysis. <i>Schizophrenia Research</i> , 2014, 152, 365-372.	1.1	20
104	Excess of homozygosity in the major histocompatibility complex in schizophrenia. <i>Human Molecular Genetics</i> , 2014, 23, 6088-6095.	1.4	18
105	High rate of disease-related copy number variations in childhood onset schizophrenia. <i>Molecular Psychiatry</i> , 2014, 19, 568-572.	4.1	116
106	Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs. <i>Nature Genetics</i> , 2013, 45, 984-994.	9.4	2,067
107	Genetic variation in <i>BDNF</i> is associated with antipsychotic treatment resistance in patients with schizophrenia. <i>Schizophrenia Research</i> , 2013, 146, 285-288.	1.1	58
108	Implication of a Rare Deletion at Distal 16p11.2 in Schizophrenia. <i>JAMA Psychiatry</i> , 2013, 70, 253.	6.0	69

#	ARTICLE	IF	CITATIONS
109	Convergent Findings for Abnormalities of the NF- $\kappa$ B Signaling Pathway in Schizophrenia. <i>Neuropsychopharmacology</i> , 2013, 38, 533-539.	2.8	59
110	Empirical Support for DSM-IV Schizoaffective Disorder: Clinical and Cognitive Validators from a Large Patient Sample. <i>PLoS ONE</i> , 2013, 8, e63734.	1.1	5
111	Coding and Noncoding Gene Expression Biomarkers in Mood Disorders and Schizophrenia. <i>Disease Markers</i> , 2013, 35, 11-21.	0.6	26
112	The Variance of Identity-by-Descent Sharing in the Wright-Fisher Model. <i>Genetics</i> , 2013, 193, 911-928.	1.2	38
113	Genome-wide association study implicates NDST3 in schizophrenia and bipolar disorder. <i>Nature Communications</i> , 2013, 4, 2739.	5.8	101
114	Runs of Homozygosity Implicate Autozygosity as a Schizophrenia Risk Factor. <i>PLoS Genetics</i> , 2012, 8, e1002656.	1.5	109
115	The Field of Schizophrenia: Strengths, Weaknesses, Opportunities, and Threats. <i>Schizophrenia Bulletin</i> , 2012, 38, 1-4.	2.3	6
116	Molecular Genetics of the Psychosis Phenotype. <i>Canadian Journal of Psychiatry</i> , 2012, 57, 1-8.	0.9	0
117	Molecular Genetics of the Psychosis Phenotype. <i>Canadian Journal of Psychiatry</i> , 2012, 57, 446-453.	0.9	8
118	Implications for health and disease in the genetic signature of the Ashkenazi Jewish population. <i>Genome Biology</i> , 2012, 13, R2.	13.9	48
119	Risk Factors for Psychosis: Impaired Social and Role Functioning. <i>Schizophrenia Bulletin</i> , 2012, 38, 1247-1257.	2.3	206
120	Association Between Common Variants Near the Melanocortin 4 Receptor Gene and Severe Antipsychotic Drug-Induced Weight Gain. <i>Archives of General Psychiatry</i> , 2012, 69, 904.	13.8	165
121	Length Distributions of Identity by Descent Reveal Fine-Scale Demographic History. <i>American Journal of Human Genetics</i> , 2012, 91, 809-822.	2.6	240
122	Pharmacogenetics in psychiatry: translating research into clinical practice. <i>Molecular Psychiatry</i> , 2012, 17, 760-769.	4.1	76
123	Length Distributions of Identity by Descent Reveal Fine-Scale Demographic History. <i>American Journal of Human Genetics</i> , 2012, 91, 1150.	2.6	7
124	In Vivo MicroRNA Detection and Quantitation in Cerebrospinal Fluid. <i>Journal of Molecular Neuroscience</i> , 2012, 47, 243-248.	1.1	64
125	Genetic architecture of prostate cancer in the Ashkenazi Jewish population. <i>British Journal of Cancer</i> , 2011, 105, 864-869.	2.9	10
126	Genome-wide association study identifies five new schizophrenia loci. <i>Nature Genetics</i> , 2011, 43, 969-976.	9.4	1,758



#	ARTICLE	IF	CITATIONS
127	Cognitive and symptomatic predictors of functional disability in schizophrenia. <i>Schizophrenia Research</i> , 2011, 126, 257-264.	1.1	162
128	Antipsychotic drugs and obesity. <i>Trends in Molecular Medicine</i> , 2011, 17, 97-107.	3.5	256
129	Fine mapping of ZNF804A and genome-wide significant evidence for its involvement in schizophrenia and bipolar disorder. <i>Molecular Psychiatry</i> , 2011, 16, 429-441.	4.1	250
130	GWA study data mining and independent replication identify cardiomyopathy-associated 5 (CMYA5) as a risk gene for schizophrenia. <i>Molecular Psychiatry</i> , 2011, 16, 1117-1129.	4.1	67
131	Genome-wide linkage scan of major depressive disorder in two Dagestan genetic isolates. <i>Open Medicine (Poland)</i> , 2011, 6, 616-624.	0.6	3
132	Candidate Gene Analysis Identifies a Polymorphism in <i>HLA-DQB1</i> Associated With Clozapine-Induced Agranulocytosis. <i>Journal of Clinical Psychiatry</i> , 2011, 72, 458-463.	1.1	124
133	DRD2 promoter region variation predicts antipsychotic-induced weight gain in first episode schizophrenia. <i>Pharmacogenetics and Genomics</i> , 2010, 20, 569-572.	0.7	68
134	Novel multi-nucleotide polymorphisms in the human genome characterized by whole genome and exome sequencing. <i>Nucleic Acids Research</i> , 2010, 38, 6102-6111.	6.5	44
135	A Schizophrenia Risk Gene, ZNF804A, Influences Neuroanatomical and Neurocognitive Phenotypes. <i>Neuropsychopharmacology</i> , 2010, 35, 2284-2291.	2.8	87
136	D <sub>2</sub> Receptor Genetic Variation and Clinical Response to Antipsychotic Drug Treatment: A Meta-Analysis. <i>American Journal of Psychiatry</i> , 2010, 167, 763-772.	4.0	192
137	Association of Genetic Variation in the <i>MET</i> Proto-Oncogene With Schizophrenia and General Cognitive Ability. <i>American Journal of Psychiatry</i> , 2010, 167, 436-443.	4.0	40
138	Meta-Analysis of Genetic Variation in DTNBP1 and General Cognitive Ability. <i>Biological Psychiatry</i> , 2010, 68, 1126-1133.	0.7	43
139	Cannabis use disorders in schizophrenia: Effects on cognition and symptoms. <i>Schizophrenia Research</i> , 2010, 120, 95-100.	1.1	62
140	Molecular differentiation of schizoaffective disorder from schizophrenia using <i>BDNF</i> haplotypes. <i>British Journal of Psychiatry</i> , 2009, 194, 313-318.	1.7	36
141	DTNBP1 is associated with imaging phenotypes in schizophrenia. <i>Human Brain Mapping</i> , 2009, 30, 3783-3794.	1.9	32
142	Lack of an inverse relationship between duration of untreated psychosis and cognitive function in first episode schizophrenia. <i>Schizophrenia Research</i> , 2009, 107, 262-266.	1.1	52
143	The serotonin transporter gene and disease modification in psychosis: Evidence for systematic differences in allelic directionality at the 5-HTTLPR locus. <i>Schizophrenia Research</i> , 2009, 111, 103-108.	1.1	40
144	Lower Orbital Frontal White Matter Integrity in Adolescents With Bipolar I Disorder. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2009, 48, 79-86.	0.3	111

#	ARTICLE	IF	CITATIONS
145	Pharmacogenetics of antipsychotic-induced side effects. <i>Dialogues in Clinical Neuroscience</i> , 2009, 11, 405-415.	1.8	50
146	Genetic variation in the DAOA gene complex: Impact on susceptibility for schizophrenia and on cognitive performance. <i>Schizophrenia Research</i> , 2008, 103, 169-177.	1.1	28
147	Patterns of stress in schizophrenia. <i>Psychiatry Research</i> , 2008, 160, 38-46.	1.7	41
148	DISC1 is associated with prefrontal cortical gray matter and positive symptoms in schizophrenia. <i>Biological Psychology</i> , 2008, 79, 103-110.	1.1	88
149	Gray matter structural alterations in obsessive-compulsive disorder: Relationship to neuropsychological functions. <i>Psychiatry Research - Neuroimaging</i> , 2008, 164, 123-131.	0.9	53
150	Cognitive deficits in schizophrenia: short-term and long-term. <i>World Psychiatry</i> , 2008, 7, 29-30.	4.8	7
151	Predictors of Remission, Schizophrenia, and Bipolar Disorder in Adolescents with Brief Psychotic Disorder or Psychotic Disorder Not Otherwise Specified Considered At Very High Risk for Schizophrenia. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2008, 18, 475-490.	0.7	50
152	The Genetics of Symptom-Based Phenotypes: Toward a Molecular Classification of Schizophrenia. <i>Schizophrenia Bulletin</i> , 2008, 34, 1047-1053.	2.3	80
153	Elucidating the relationship between DISC1, NDEL1 and NDE1 and the risk for schizophrenia: Evidence of epistasis and competitive binding. <i>Human Molecular Genetics</i> , 2008, 17, 2462-2473.	1.4	101
154	Gray Matter Structural Alterations in Psychotropic Drug-Naive Pediatric Obsessive-Compulsive Disorder: An Optimized Voxel-Based Morphometry Study. <i>American Journal of Psychiatry</i> , 2008, 165, 1299-1307.	4.0	124
155	Clinical and Neuropsychological Correlates of White Matter Abnormalities in Recent Onset Schizophrenia. <i>Neuropsychopharmacology</i> , 2008, 33, 976-984.	2.8	220
156	Pharmacogenomics Applications in Psychiatric Disorders. <i>Methods in Pharmacology and Toxicology</i> , 2008, , 369-394.	0.1	1
157	Runs of homozygosity reveal highly penetrant recessive loci in schizophrenia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 19942-19947.	3.3	367
158	Cognitive Improvement After Treatment With Second-Generation Antipsychotic Medications in First-Episode Schizophrenia. <i>Archives of General Psychiatry</i> , 2007, 64, 1115.	13.8	357
159	Anterior cingulate grey-matter deficits and cannabis use in first-episode schizophrenia. <i>British Journal of Psychiatry</i> , 2007, 190, 230-236.	1.7	82
160	Localisation of increased prefrontal white matter in pathological liars. <i>British Journal of Psychiatry</i> , 2007, 190, 174-175.	1.7	41
161	DTNBP1 genotype influences cognitive decline in schizophrenia. <i>Schizophrenia Research</i> , 2007, 89, 169-172.	1.1	102
162	Disrupted in Schizophrenia 1 Genotype and Positive Symptoms in Schizophrenia. <i>Biological Psychiatry</i> , 2007, 61, 1208-1210.	0.7	73

#	ARTICLE	IF	CITATIONS
163	Genomics and the future of pharmacotherapy in psychiatry. <i>International Review of Psychiatry</i> , 2007, 19, 523-530.	1.4	47
164	Analysis of TBX1 Variation in Patients with Psychotic and Affective Disorders. <i>Molecular Medicine</i> , 2007, 13, 407-414.	1.9	16
165	Converging evidence for a pseudoautosomal cytokine receptor gene locus in schizophrenia. <i>Molecular Psychiatry</i> , 2007, 12, 572-580.	4.1	255
166	Early identification and high-risk strategies for bipolar disorder. <i>Bipolar Disorders</i> , 2007, 9, 324-338.	1.1	108
167	Can Antidepressants Be Used to Treat the Schizophrenia Prodrome?. <i>Journal of Clinical Psychiatry</i> , 2007, 68, 546-557.	1.1	185
168	Generalized and Specific Neurocognitive Deficits in Prodromal Schizophrenia. <i>Biological Psychiatry</i> , 2006, 59, 863-871.	0.7	364
169	Early-onset schizophrenia is associated with impaired adolescent development of attentional capacity using the identical pairs continuous performance test. <i>Schizophrenia Research</i> , 2006, 81, 157-166.	1.1	25
170	Deficits in memory strategy use are related to verbal memory impairments in adolescents with schizophrenia-spectrum disorders. <i>Schizophrenia Research</i> , 2006, 85, 201-212.	1.1	39
171	COMT genotype and manic symptoms in schizophrenia. <i>Schizophrenia Research</i> , 2006, 87, 28-31.	1.1	22
172	Increased stress and smaller anterior hippocampal volume. <i>NeuroReport</i> , 2006, 17, 1825-1828.	0.6	24
173	DRD2 Promoter Region Variation as a Predictor of Sustained Response to Antipsychotic Medication in First-Episode Schizophrenia Patients. <i>American Journal of Psychiatry</i> , 2006, 163, 529-531.	4.0	146
174	Dysbindin Genotype and Negative Symptoms in Schizophrenia. <i>American Journal of Psychiatry</i> , 2006, 163, 532-534.	4.0	101
175	Cognitive Development in Schizophrenia: Follow-Back from the First Episode. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2006, 28, 270-282.	0.8	107
176	Genetic variation in DTNBP1 influences general cognitive ability. <i>Human Molecular Genetics</i> , 2006, 15, 1563-1568.	1.4	160
177	DISC1 and neurocognitive function in schizophrenia. <i>NeuroReport</i> , 2005, 16, 1399-1402.	0.6	105
178	Brain morphometry using diffusion-weighted magnetic resonance imaging: application to schizophrenia. <i>NeuroReport</i> , 2005, 16, 1455-1459.	0.6	41
179	Prefrontal white matter in pathological liars. <i>British Journal of Psychiatry</i> , 2005, 187, 320-325.	1.7	100
180	Prospective Study of Adolescents with Subsyndromal Psychosis: Characteristics and Outcome. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2005, 15, 418-433.	0.7	35

#	ARTICLE	IF	CITATIONS
181	White Matter Abnormalities in Early-Onset Schizophrenia: A Voxel-Based Diffusion Tensor Imaging Study. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2005, 44, 934-941.	0.3	115
182	COMT genetic variation confers risk for psychotic and affective disorders: a case control study. <i>Behavioral and Brain Functions</i> , 2005, 1, 19.	1.4	115
183	Volume Reduction in Prefrontal Gray Matter in Unsuccessful Criminal Psychopaths. <i>Biological Psychiatry</i> , 2005, 57, 1103-1108.	0.7	265
184	Neurocognitive Profile in Adolescents with Early-Onset Schizophrenia: Clinical Correlates. <i>Biological Psychiatry</i> , 2005, 58, 705-712.	0.7	111
185	Nonspecific and attenuated negative symptoms in patients at clinical high-risk for schizophrenia. <i>Schizophrenia Research</i> , 2004, 68, 37-48.	1.1	207
186	Hippocampal structural asymmetry in unsuccessful psychopaths. <i>Biological Psychiatry</i> , 2004, 55, 185-191.	0.7	185
187	Left middle temporal gyrus activation during a phonemic discrimination task. <i>NeuroReport</i> , 2004, 15, 389-393.	0.6	31
188	Treatment of the Schizophrenia Prodrome. , 2004, , 303-323.		2
189	Smaller Anterior Hippocampal Formation Volume in Antipsychotic-Naive Patients With First-Episode Schizophrenia. <i>American Journal of Psychiatry</i> , 2003, 160, 2190-2197.	4.0	147
190	Impairments in Perceptual Competency and Maintenance on a Visual Delayed Match-to-Sample Test in First-Episode Schizophrenia. <i>Archives of General Psychiatry</i> , 2003, 60, 238.	13.8	90
191	The Schizophrenia Prodrome Revisited: A Neurodevelopmental Perspective. <i>Schizophrenia Bulletin</i> , 2003, 29, 633-651.	2.3	327
192	The Assessment of "Prodromal Schizophrenia": Unresolved Issues and Future Directions. <i>Schizophrenia Bulletin</i> , 2003, 29, 717-728.	2.3	67
193	Corpus Callosum Abnormalities in Psychopathic Antisocial Individuals. <i>Archives of General Psychiatry</i> , 2003, 60, 1134.	13.8	202
194	Prefrontal Structural and Functional Deficits in Schizotypal Personality Disorder. <i>Schizophrenia Bulletin</i> , 2002, 28, 501-513.	2.3	36
195	The schizophrenia prodrome: treatment and high-risk perspectives. <i>Schizophrenia Research</i> , 2002, 54, 177-186.	1.1	132
196	Treatment of the schizophrenia prodrome: is it presently ethical?. <i>Schizophrenia Research</i> , 2001, 51, 31-38.	1.1	129
197	Increased height and bulk in antisocial personality disorder and its subtypes. <i>Psychiatry Research</i> , 2001, 105, 211-219.	1.7	37
198	The Timing of Neurodevelopmental Abnormality in Schizophrenia: An Integrative Review of the Neuroimaging Literature. <i>CNS Spectrums</i> , 2001, 6, 233-255.	0.7	6

#	ARTICLE	IF	CITATIONS
199	Autonomic stress reactivity and executive functions in successful and unsuccessful criminal psychopaths from the community.. Journal of Abnormal Psychology, 2001, 110, 423-432.	2.0	205
200	Reduced right hemisphere activation in severely abused violent offenders during a working memory task: An fMRI study. Aggressive Behavior, 2001, 27, 111-129.	1.5	83
201	Reduced Prefrontal Gray Matter Volume and Reduced Autonomic Activity in Antisocial Personality Disorder. Archives of General Psychiatry, 2000, 57, 119.	13.8	889
202	Reduced anterior cingulate gyrus volume correlates with executive dysfunction in men with first-episode schizophrenia. Schizophrenia Research, 2000, 43, 97-108.	1.1	94
203	93. Behavioral profiles of adolescents putatively prodromal for schizophrenia. Biological Psychiatry, 2000, 47, S28.	0.7	0
204	94. Neuropsychological correlates of mesiotemporal volumes in schizophrenia. Biological Psychiatry, 2000, 47, S28-S29.	0.7	0
205	95. Smooth pursuit eye movement dysfunction in patients at clinical risk for schizophrenia. Biological Psychiatry, 2000, 47, S29.	0.7	0
206	97. The hillside RAPP clinic: why the sudden interest in the schizophrenia prodrome?. Biological Psychiatry, 2000, 47, S29-S30.	0.7	1
207	98. A self-report questionnaire to screen for prodromal schizophrenia. Biological Psychiatry, 2000, 47, S30.	0.7	0
208	330. Atypical antipsychotic effects on fMRI in drug-naive schizophrenia. Biological Psychiatry, 2000, 47, S99.	0.7	1
209	Orbital Frontal and Amygdala Volume Reductions in Obsessive-compulsive Disorder. Archives of General Psychiatry, 1999, 56, 913.	13.8	328
210	Investigation of frontal lobe subregions in first-episode schizophrenia1This study was presented in part at the 1996 Meeting of the Society for Research in Psychopathology in Atlanta, GA, and the 1997 Meeting of the International Congress on Schizophrenia Research in Colorado Springs, CO.1. Psychiatry Research - Neuroimaging, 1999, 90, 1-15.	0.9	101
211	MRI landmark shape analysis of neuroanatomy in first-episode schizophrenia. Schizophrenia Research, 1997, 24, 151.	1.1	0
212	Parcellation of the frontal lobes in first-episode schizophrenia. Schizophrenia Research, 1997, 24, 158.	1.1	0
213	Neuroanatomical bases of electrodermal hypo-responding: A cluster analytic study. International Journal of Psychophysiology, 1996, 22, 141-153.	0.5	15
214	Neurodevelopmental processes in schizophrenia and schizotypal personality disorder. , 1995, , 56-76.		9
215	Schizotypal status as a developmental stage in studies of risk for schizophrenia. , 1995, , 107-132.		13
216	Cognitive-perceptual, Interpersonal, and Disorganized Features of Schizotypal Personality. Schizophrenia Bulletin, 1994, 20, 191-201.	2.3	519

#	ARTICLE	IF	CITATIONS
217	Brain Imaging Research on Electrodermal Activity in Humans. , 1993, , 115-135.		8
218	Specificity in the correlation of verbal memory and hippocampal neuron loss: Dissociation of memory, language, and verbal intellectual ability. Neuropsychology, Development and Cognition Section A: Journal of Clinical and Experimental Neuropsychology, 1992, 14, 662-672.	1.4	152
219	An evaluation of structural and functional prefrontal deficits in schizophrenia: MRI and neuropsychological measures. Psychiatry Research - Neuroimaging, 1992, 45, 123-137.	0.9	93
220	Russell's adaptation of the Wechsler Memory Scale as an index of hippocampal pathology. Journal of Epilepsy, 1992, 5, 24-30.	0.4	49
221	Pre-frontal structural and functional deficits associated with individual differences in schizotypal personality. Schizophrenia Research, 1992, 7, 237-247.	1.1	131
222	Quantitative magnetic resonance imaging in temporal lobe epilepsy: Relationship to neuropathology and neuropsychological function. Annals of Neurology, 1992, 31, 629-637.	2.8	401